BioPharmX (BPMX) EPS Projected to Increase CEOs
Post# of 223
CEOs don't wake up in the morning hoping that this is the day they get to report negative earnings per share. Companies want to make money, not lose it, and it's safe for an investor to assume that a negative EPS is not a good thing. That said, sometimes a negative EPS is not as big a deal. Biotechs often spend years losing money as they develop commercially viable products. Startups that are just getting off the ground might need time to build up sales and profitability. If such a company continues to narrow its losses and move toward a positive EPS, that's a good sign.
-Cam Merritt